Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CAMX
Cambiar Aggressive Value ETF
34.6
9
USD
0.00%
Sector:
Financial
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.20%
Monthly Change
+0.52%
6 month change
+6.44%
Year Change
+6.44%
Previous Close
34.6
2
Open
34.6
9
Low
34.6
9
High
34.6
9
Volume
3
Markets
US ETFs
CAMX
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Overview
All holdings
Heatmap
Top holdings
Market Value
Shares
Weight %
ELV
ELEVANCE HEALTH, INC.
3.764 M
10.000 K
5.695%
UBER
UBER TECHNOLOGIES, INC.
3.432 M
46.000 K
5.193%
ON
ON SEMICONDUCTOR CORPORATION
2.923 M
29.000 K
4.423%
BMY
BRISTOL-MYERS SQUIBB COMPANY
2.712 M
44.768 K
4.104%
HON
HONEYWELL INTERNATIONAL INCORPORATION
2.679 M
12.500 K
4.053%
MAS
MASCO CORPORATION
2.643 M
36.800 K
3.999%
NXPI
NXP Semiconductors N.V.
2.642 M
9 000.000
3.998%
DAL
DELTA AIR LINES, INC.
2.611 M
38.400 K
3.950%
Airbus SE
2.575 M
50.000 K
3.895%
UNP
UNION PACIFIC CORPORATION
2.560 M
9 500.000
3.873%
ALGN
ALIGN TECHNOLOGY, INC.
2.503 M
14.222 K
3.787%
DEO
DIAGEO PLC
2.420 M
30.000 K
3.661%
A
AMRZ
Amrize AG
2.413 M
44.870 K
3.651%
GOOGL
ALPHABET INC.
2.397 M
6 228.000
3.626%
CNC
CENTENE CORPORATION
2.362 M
44.000 K
3.574%
Nintendo Co., Ltd.
2.337 M
192.000 K
3.535%
MDT
MEDTRONIC PUBLIC LIMITED COMPANY
2.135 M
26.363 K
3.230%
APTV
APTIV PLC
1.989 M
33.000 K
3.009%
SHIMANO INC.
1.982 M
188.980 K
2.999%
LH
LABCORP HOLDINGS INC.
1.746 M
6 800.000
2.642%
1
2
News
Camurus reports Q4 revenue miss, lowers 2026 outlook
FDA accepts Camurus’ resubmission for acromegaly treatment Oclaiz
Camurus Q3 2025 slides: Revenue up 18% but stock dips on lowered guidance
Camurus cuts 2025 revenue forecast as Buvidal sales miss estimates
Camurus Q2 2025 slides reveal 52% revenue surge and key regulatory milestones
Earnings call transcript: Camurus AB Q2 2025 earnings beat expectations
Camurus Q2 2025 slides: Record revenue and profit amid product portfolio expansion
Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal ® incretins
Camurus Q1 2025 slides: record profitability despite market challenges
Camurus stock falls on 1Q revenue miss